Nanobiotix: Trading Halt on Euronext Paris for a Global Securities Offering
Nanobiotix announces a temporary suspension of trading of its ordinary shares on Euronext Paris starting from the market opening at 9:00 AM (CEST) on Thursday, in connection with a global securities offering.
The biotechnology company temporarily suspends the trading of its ordinary shares on the regulated Euronext market in Paris. This suspension is part of a global offering consisting of two components: a public offering of American Depositary Shares (ADS) in the United States, and an offering of ordinary shares along with pre-financed warrant subscriptions reserved for qualified investors in Europe and certain other countries (excluding the United States and Canada).
The suspension will allow for the confirmation of allocations to investors and the announcement of the final terms of the global offering. Trading on Euronext Paris is expected to resume on May 21, 2026, around 3:30 PM (Paris time) / 9:30 AM (New York time).
About Nanobiotix
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Nanobiotix is a clinical-stage biotechnology company in advanced phase, founded in 2003, headquartered in Paris. It has been listed on Euronext in Paris since 2012 and on the Nasdaq Global Select Market since December 2020. The company has subsidiaries, notably in Cambridge, Massachusetts, and owns over 25 patent families associated with three nanotechnology platforms covering oncology, bioavailability and biodistribution, as well as central nervous system disorders.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 3,6 millions d'euros
Quarterly revenue: 3,6 millions d'euros
Net income: -34,3 millions d'euros
Guidance from the release
« la Société estime qu'elle disposera des liquidités suffisantes pour faire face à ses obligations financières […] pendant au moins les 12 prochains mois […] pas de doute substantiel quant à la capacité de la Société à poursuivre son activité » ; CP du 24/09 : trésorerie de 110,9 M€ « permettront de financer ses opérations jusqu'en 2029 »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
